
CONTENTS

FOREWORD	ix
PREFACE	xiii
CONTRIBUTORS	xvii

PART I PREFORMULATION AND DEVELOPMENT OF STABILITY-INDICATING ASSAYS: BIOPHYSICAL CHARACTERIZATION TECHNIQUES 1

1 THE STRUCTURE OF BIOLOGICAL THERAPEUTICS 3

Sheryl Martin-Moe, Tim Osslund, Y. John Wang, Tahir Mahmood, Rohini Deshpande, and Susan Hershenson

2 CHEMICAL INSTABILITY IN PEPTIDE AND PROTEIN PHARMACEUTICALS 41

Elizabeth M. Topp, Lei Zhang, Hong Zhao, Robert W. Payne, Gabriel J. Evans, and Mark Cornell Manning

3 PHYSICAL STABILITY OF PROTEIN PHARMACEUTICALS 69

Byeong S. Chang and Bernice Yeung

4 IMMUNOGENICITY OF THERAPEUTIC PROTEINS 105

Steven J. Swanson

5 PREFORMULATION RESEARCH: ASSESSING PROTEIN SOLUTION BEHAVIOR DURING EARLY DEVELOPMENT 119

Bernardo Perez-Ramirez, Nicholas Guziewicz, and Robert Simler

6 FORMULATION DEVELOPMENT OF PHASE 1–2 BIOPHARMACEUTICALS: AN EFFICIENT AND TIMELY APPROACH 147

Nicholas W. Warne

7	LATE-STAGE FORMULATION DEVELOPMENT AND CHARACTERIZATION OF BIOPHARMACEUTICALS	161
	<i>Adeola O. Grillo</i>	
8	AN EMPIRICAL PHASE DIAGRAM–HIGH-THROUGHPUT SCREENING APPROACH TO THE CHARACTERIZATION AND FORMULATION OF BIOPHARMACEUTICALS	173
	<i>Sangeeta B. Joshi, Akhilesh Bhambhani, Yuhong Zeng, and C. Russell Middaugh</i>	
9	FLUORESCENCE AND PHOSPHORESCENCE METHODS TO PROBE PROTEIN STRUCTURE AND STABILITY IN ICE: THE CASE OF AZURIN	207
	<i>Giovanni B. Strambini</i>	
10	APPLICATIONS OF SEDIMENTATION VELOCITY ANALYTICAL ULTRACENTRIFUGATION	231
	<i>Tom Laue</i>	
11	FIELD FLOW FRACTIONATION WITH MULTIANGLE LIGHT SCATTERING FOR MEASURING PARTICLE SIZE DISTRIBUTIONS OF VIRUS-LIKE PARTICLES	253
	<i>Joyce A. Sweeney and Christopher Hamm</i>	
12	LIGHT-SCATTERING TECHNIQUES AND THEIR APPLICATION TO FORMULATION AND AGGREGATION CONCERNS	269
	<i>Michael Larkin and Philip Wyatt</i>	
	PART II DEVELOPMENT OF A FORMULATION FOR LIQUID DOSAGE FORM	307
13	EFFECTIVE APPROACHES TO FORMULATION DEVELOPMENT OF BIOPHARMACEUTICALS	309
	<i>Rajiv Nayar and Mitra Mosharraf</i>	
14	PREDICTION OF AGGREGATION PROPENSITY FROM PRIMARY SEQUENCE INFORMATION	329
	<i>Mark Cornell Manning, Gabriel J. Evans, Cody M. Van Pelt, and Robert W. Payne</i>	
15	HIGH-CONCENTRATION ANTIBODY FORMULATIONS	349
	<i>Steven J. Shire, Jun Liu, Wolfgang Friess, Susanne Jörg, and Hanns-Christian Mahler</i>	

16	DEVELOPMENT OF FORMULATIONS FOR THERAPEUTIC MONOCLONAL ANTIBODIES AND Fc FUSION PROTEINS	383
	<i>Sampathkumar Krishnan, Monica M. Pallitto, and Margaret S. Ricci</i>	
17	REVERSIBLE SELF-ASSOCIATION OF PHARMACEUTICAL PROTEINS: CHARACTERIZATION AND CASE STUDIES	429
	<i>Vikas K. Sharma, Harminster Bajaj, and Devendra S. Kalonia</i>	
PART III	DEVELOPMENT OF A FORMULATION FOR LYOPHILIZED DOSAGE FORM	457
18	DESIGN OF A FORMULATION FOR FREEZE DRYING	459
	<i>Feroz Jameel and Mike J. Pikal</i>	
19	PROTEIN CONFORMATION AND REACTIVITY IN AMORPHOUS SOLIDS	493
	<i>Lei Zhang, Sandipan Sinha, and Elizabeth M. Topp</i>	
20	THE IMPACT OF BUFFER ON SOLID-STATE PROPERTIES AND STABILITY OF FREEZE-DRIED DOSAGE FORMS	507
	<i>Evgenyi Y. Shalaev and Larry A. Gatlin</i>	
21	STABILIZATION OF LYOPHILIZED PHARMACEUTICALS BY CONTROL OF MOLECULAR MOBILITY: IMPACT OF THERMAL HISTORY	521
	<i>Suman Luthra and Michael J. Pikal</i>	
22	STRUCTURAL ANALYSIS OF PROTEINS IN DRIED MATRICES	549
	<i>Andrea Hawe, Sandipan Sinha, Wolfgang Friess, and Wim Jiskoot</i>	
23	THE IMPACT OF FORMULATION AND DRYING PROCESSES ON THE CHARACTERISTICS AND PERFORMANCE OF BIOPHARMACEUTICAL POWDERS	565
	<i>Vu L. Truong and Ahmad M. Abdul-Fattah</i>	
PART IV	MANUFACTURING SCIENCES	587
24	MANUFACTURING FUNDAMENTALS FOR BIOPHARMACEUTICALS	589
	<i>Maninder Hora</i>	
25	PROTEIN STABILITY DURING BIOPROCESSING	605
	<i>Mark Cornell Manning, Gabriel J. Evans, and Robert W. Payne</i>	

26	FREEZING AND THAWING OF PROTEIN SOLUTIONS	625
	<i>Satish K. Singh and Sandeep Nema</i>	
27	STRATEGIES FOR BULK STORAGE AND SHIPMENT OF PROTEINS	677
	<i>Feroz Jameel, Chakradhar Padala, and Theodore W. Randolph</i>	
28	DRYING PROCESS METHODS FOR BIOPHARMACEUTICAL PRODUCTS: AN OVERVIEW	705
	<i>Ahmad M. Abdul-Fattah and Vu L. Truong</i>	
29	SPRAY DRYING OF BIOPHARMACEUTICALS AND VACCINES	739
	<i>Jim Searles and Govindan Mohan</i>	
30	DEVELOPMENT AND OPTIMIZATION OF THE FREEZE-DRYING PROCESSES	763
	<i>Feroz Jameel and Jim Searles</i>	
31	CONSIDERATIONS FOR SUCCESSFUL LYOPHILIZATION PROCESS SCALE-UP, TECHNOLOGY TRANSFER, AND ROUTINE PRODUCTION	797
	<i>Samir U. Sane and Chung C. Hsu</i>	
32	PROCESS ROBUSTNESS IN FREEZE DRYING OF BIOPHARMACEUTICALS	827
	<i>D. Q. Wang, D. MacLean, and X. Ma</i>	
33	FILLING PROCESSES AND TECHNOLOGIES FOR LIQUID BIOPHARMACEUTICALS	839
	<i>Ananth Sethuraman, Xiaogang Pan, Bhavya Mehta, and Vinay Radhakrishnan</i>	
34	LEACHABLES AND EXTRACTABLES	857
	<i>Jim Castner, Pedro Benites, and Michael Bresnick</i>	
35	PRIMARY CONTAINER AND CLOSURE SELECTION FOR BIOPHARMACEUTICALS	881
	<i>Olivia Henderson</i>	
36	PREFILLED SYRINGES FOR BIOPHARMACEUTICALS	897
	<i>Robert Swift</i>	
37	IMPACT OF MANUFACTURING PROCESSES ON DRUG PRODUCT STABILITY AND QUALITY	917
	<i>Nitin Rathore, Rahul S. Rajan, and Erwin Freund</i>	
	INDEX	941